Background Lenvatinib demonstrated a treatment effect on overall survival by the statistical
confirmation of non-inferiority to sorafenib for the first-line treatment of uHCC. The objective …

Background Lenvatinib and atezolizumab plus bevacizumab (A+ B) have been used for
unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies …

Abstract Background and Aim Lenvatinib is a standard of care option in first‐line therapy of
advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in …

Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but
prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and …

317 Background: In the phase 3 REFLECT study, lenvatinib (LEN) demonstrated a treatment
effect on overall survival (OS) by statistical confirmation of non-inferiority to sorafenib (SOR) …

Background: The aims of this study were to evaluate the efficacy of additional treatment,
especially lenvatinib-transarterial chemoembolization (TACE) sequential therapy, for …

We sought to investigate the clinical profile (s) associated with the discontinuation of
lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable …

Aim: Atezolizumab plus bevacizumab (atezo+ bev) shows a good overall survival (OS) in
advanced hepatocellular carcinoma (HCC) patients. However, the OS of patients with …

Simple Summary Immune checkpoint inhibitor therapy has been rapidly developed for the
treatment of unresectable hepatocellular carcinoma (HCC). In the IMbrave150 trial …

380 Background: LAUNCH is a multicenter, randomized, open-label, parallel-group phase 3
trial, aiming to assess the efficacy and safety of lenvatinib plus TACE compared with …